Aarti Pharmalabs Limited will hold its 7th Annual General Meeting on Tuesday, September 22, 2026. The meeting is scheduled for 11:00 am and will be conducted through video conferencing or other audio-visual means.

The company dispatched the AGM notice and annual report for FY26 via email on August 29, 2026. Shareholders holding shares as of the cut-off date of Tuesday, September 15, 2026, are eligible to vote.

E-Voting Details

Members can cast their votes electronically using the facility provided by National Securities Depository Limited. The remote e-voting period begins on Saturday, September 19, 2026, at 9:00 am and ends on Monday, September 21, 2026, at 5:00 pm.

Once a vote is cast, it cannot be changed. Members who vote remotely can still attend the meeting but cannot vote again. Those who do not vote remotely can cast their votes during the meeting.

Dividend Record Date

The record date for determining dividend entitlement for FY26 is Tuesday, September 15, 2026. The final dividend payment will be made on or before Tuesday, October 20, 2026, subject to shareholder approval at the AGM.

What the Numbers Show

The company has aligned its dividend record date with the e-voting cut-off date of September 15, 2026. This synchronization ensures that shareholders eligible to participate in corporate governance decisions are also entitled to the final dividend payout for the fiscal year.

Aarti Pharmalabs Limited filed its Business Responsibility and Sustainability Report (BRSR) for the financial year ending March 31, 2026, with the Bombay Stock Exchange and the National Stock Exchange of India Limited on August 29, 2026. The filing complies with Regulation 34(2)(f) of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.

The company reported a turnover of ₹17,975.5 crore and a net worth of ₹19,740.9 crore for the period. The standalone report covers operations across 15 plants and three offices in India, serving customers in 51 countries. Exports accounted for approximately 55.93% of total turnover.

Operational and Financial Overview

Aarti Pharmalabs operates primarily in the manufacturing of Active Pharmaceutical Ingredients (APIs), pharmaceutical intermediates, and xanthine derivatives. The API segment contributed 51% of turnover, while xanthine derivatives contributed 49%. The company employs 2,033 permanent employees and 2,185 workers as of March 31, 2026.

Environmental Performance

The company disclosed significant reductions in energy intensity and greenhouse gas emissions per unit of turnover. Total energy consumption from non-renewable sources fell to 7,82,556.47 GJ from 12,99,598.24 GJ in the prior year. Scope 1 emissions decreased to 92,294.78 metric tonnes of CO2 equivalent, while Scope 2 emissions dropped sharply to 63,582.46 metric tonnes from 105,577.65 metric tonnes.

Aarti Pharmalabs implemented a Zero Liquid Discharge mechanism across all units, recycling 100% of liquid waste. The company also installed a 15 MW solar power plant in Akola, Maharashtra, which saved 84,393.32 GJ of energy during the fiscal year.

Governance and Social Metrics

The board comprises 12 directors, with women representing 33.3% of the membership. The company reported zero fatalities and zero lost-time injury frequency rates for both employees and workers. Training coverage reached 100% for all employees and workers on human rights issues.

The company paid a penalty of ₹2.6 lakh to the Office of the Assistant Commissioner, CGST and Central Excise, Vapi, regarding alleged excess availment of Input Tax Credit for FY23 and FY24. No appeals were preferred against this order.

What the Numbers Show

A notable divergence exists between the company's waste generation volume and its recycling efficiency. While total waste generated increased significantly to 26,229.55 metric tonnes from 15,550.04 metric tonnes in the prior year, the amount recycled more than doubled to 12,835.85 metric tonnes. This suggests that the rise in waste is largely associated with production scale-up that the existing recycling infrastructure can absorb, rather than a decline in waste management efficacy.